ArticleEuropean urology open science2026
Rapid Clearance of microRNA-371a-3p: A Longitudinal Study of Serum Levels in Patients with Localized Testicular Germ Cell Tumors.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Rapid clearance after treatment is a cornerstone feature of valuable tumor markers. microRNA-371a-3p (M371) has much promise to become a useful biomarker of germ cell tumors (GCTs). However, little is known about its velocity of decay. This study aimed to systematically analyze the kinetics of decline of M371 serum levels. Methods: A total of 53 patients with clinical stage (CS) I GCT had measurements of M371 levels before orchiectomy and five measurements postoperatively, four within the first 48 h, and one after 2 wk. The commercial M371 test was used to measure serum levels with quantitative polymerase chain reaction. Postoperative levels were statistically compared with the preoperative level. The half-life (H/L) and the absolute time to normalization (TTN) were calculated by linear interpolation. Possible associations with clinical factors were evaluated. Key findings and limitations: The median H/L of M371 was 3.8 h (interquartile range [IQR] 2.9-6.2). We found no statistical evidence that H/L was associated with the clinical factors evaluated. The absolute median TTN was 33.8 h (IQR 6.5-261.6), which was associated with the baseline value of M371. Limitations may result from baseline blood sampling several days before surgery. Conclusions and clinical implications: M371 levels in patients with CS I GCT decline with a H/L of 3.8 h postoperatively, which is much more rapid than in traditional markers. The absolute TTN of M371 is associated with the baseline value and exhibits interindividual variability. Overall, the rapid kinetic profile of M371 is another valuable feature of the novel biomarker of testicular GCTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.